Skip to Main Content

After months of deliberation, the European Commission has accepted an offer from Aspen Pharma to reduce the prices of six cancer medicines sold across Europe by an average of 73% and also ensure that supplies remain available on the continent for another decade.

The agreement comes after a high-profile investigation into price gouging in which European officials found the drug maker charged “excessive” prices for cancer medicines that were, in some cases, decades old and no longer were protected by patents. Yet Aspen charged prices that exceeded its costs by almost 300%, on average, even when considering a reasonable rate of return.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!